-+ 0.00%
-+ 0.00%
-+ 0.00%
Duopharma earnings rise to RM88.56mil
Share
Listen to the news

PETALING JAYA: Duopharma Biotech Bhd posted a net profit of RM88.56mil in the nine-month period to Sept 30, 2026 (9M26), as compared to RM68.42mil in the year-ago period, due to strong profit margins that offset a weaker topline.

According to the pharmaceutical group’s results filing with Bursa Malaysia, profit margins were supported by a more favourable product mix and lower imported active pharmaceutical ingredient costs amid the strengthening of the ringgit.

Revenue in 9M26 was RM692.29mil, down from RM707.01mil in 9M25, primarily attributable to the normalisation of public sector insulin sales following the exceptional sales recorded in the first half of 2025.

In the third quarter alone, the group recorded a higher net profit of RM27.98mil as compared to RM22.57mil in the year-ago quarter. Quarterly revenue dipped to RM210.05mil from RM222.49mil in the previously comparative quarter.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending